Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP
CME in Minutes: Education in Dermatology01/26/24 • 14 min
Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.
01/26/24 • 14 min
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/cme-in-minutes-education-in-dermatology-401482/jonathan-barker-bsc-mb-bs-md-frcp-novel-approved-and-emerging-il-36-re-56207210"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to jonathan barker, bsc, mb, bs, md, frcp - novel approved and emerging il-36 receptor inhibitors for the treatment of gpp on goodpods" style="width: 225px" /> </a>
Copy